Long‐term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.13194PMID 25858519
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Study of the Association Between Hip Fracture and Acid‐Suppressive Drug Use in a UK Primary Care Setting

  2014cited by this paper
• Safety of long-term PPI therapy.

  2013cited by this paper
• Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.

  2013cited by this paper
• The risks of PPI therapy

  2012cited by this paper
• Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5‐year follow‐up in the LOTUS trial

  2012cited by this paper
• Gastric carcinoids after long‐term use of a proton pump inhibitor

  2012cited by this paper
• Recent safety concerns with proton pump inhibitors.

  2012cited by this paper
• Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial.

  2011cited by this paper
• Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population‐based case‐control study

  2010cited by this paper
• Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium

  2010cited by this paper
• Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

  2010cited by this paper
• Long-Term Outcome of Microscopic Esophagitis in Chronic GERD Patients Treated With Esomeprazole or Laparoscopic Antireflux Surgery in the LOTUS Trial

  2010cited by this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cited by this paper
• Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis.

  2009cited by this paper
• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  2009cited by this paper
• The clinical safety of long‐term lansoprazole for the maintenance of healed erosive oesophagitis

  2009cited by this paper
• Long-term safety concerns with proton pump inhibitors.

  2009cited by this paper
• Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

  2008cited by this paper
• Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial

  2008cited by this paper
• Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia

  2008cited by this paper
• Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.

  2007cited by this paper
• Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.

  2007cited by this paper
• Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture

  2006cited by this paper
• Long-term proton pump inhibitor therapy and risk of hip fracture.

  2006cited by this paper
• A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults.

  2004cited by this paper
• Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover study

  2004cited by this paper
• Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

  2004cited by this paper
• Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea.

  2003cited by this paper
• Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study

  1996cited by this paper
• Omeprazole Therapy Causes Malabsorption of Cyanocobalamin (Vitamin B12)

  1994cited by this paper
• Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat.

  1991cited by this paper

• AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus.

  2025cites this paper
• Chemoprevention in Barrett's Esophagus: An Updated Review.

  2025cites this paper
• Prescribing Responsibly: Navigating the Tides of Deprescribing in Proton Pump Inhibitor Stewardship

  2025cites this paper
• Long-term Effects of Potassium-competitive Acid Blockers and Proton Pump Inhibitors on Gastrin, Gastric Emptying Rate, and Small Intestinal Microbiota in Rats

  2025cites this paper
• Comorbid patient with gastroesophageal reflux disease: Features of the choice of proton pump inhibitor

  2025cites this paper
• Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies

  2025cites this paper
• Association of Proton Pump Inhibitor Use With Gastric Cancer in Regions With High Prevalence of Gastric Cancer: Systematic Review and Meta-analysis

  2025cites this paper
• Analysis of the assortment and availability of drugs in medical technological documents regulating the acid-dependent diseases pharmacotherapy

  2025cites this paper
• Current Medical Controversies in Zollinger–Ellison Syndrome

  2025cites this paper
• The association of proton pump inhibitors and inflammatory bowel disease from the perspective of gut microbiota perturbation

  2025cites this paper
• Association Between Long-Term Proton Pump Inhibitor Therapy and Vitamin B12 Status: A Systematic Review and Meta-Analysis

  2025cites this paper
• Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?

  2024cites this paper
• Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis

  2024cites this paper
• PPI use is not associated with bone microarchitecture and strength assessed with HR-pQCT after three-years follow-up in patients visiting the Fracture Liaison Service.

  2024cites this paper
• Proton Pump Inhibitors and Kidney Disease: What Gives?

  2024cites this paper
• Long-Term Proton Pump Inhibitor–Acid Suppressive Treatment Can Cause Vitamin B12 Deficiency in Zollinger–Ellison Syndrome (ZES) Patients

  2024cites this paper
• Role of prescribed medication in the development of iron deficiency anaemia in adults—a case–control study

  2024cites this paper
• Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density

  2024cites this paper
• Eosinophilic oesophagitis in adults: from symptoms to therapeutic options

  2024cites this paper
• S2k guideline Gastroesophageal reflux disease and eosinophilic esophagitis of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

  2024cites this paper
• Safe use of proton-pump inhibitors.

  2023cites this paper
• Effect of Long-Term Proton Pump Inhibitor Use on Blood Vitamins and Minerals: A Primary Care Setting Study

  2023cites this paper
• Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis

  2023cites this paper
• The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance

  2023cites this paper
• Effect of 90 Days Sub-chronic Administration of Omeprazole (A Proton Pump Inhibitor) on Haematological, Biochemical, Antioxidant, Reproductive and Histopathological Parameters in Male and Female Rats

  2023influential citation
• Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper

  2023cites this paper
• S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013

  2023cites this paper
• Long‐term efficacy of antireflux mucosectomy in patients with refractory gastroesophageal reflux disease

  2023cites this paper
• Proton pump inhibitors' use and risk of iron deficiency anaemia: a systematic review and meta-analysis.

  2022cites this paper
• The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD)

  2022cites this paper
• Evidence-based treatments for eosinophilic esophagitis: insights for the clinician

  2022cites this paper
• Proton Pump Inhibitors: Promising Role in the Prophylaxis and Symptom Control of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

  2022cites this paper
• Proton pump inhibitors: Assessment of side effects and application in COVID-19 infection

  2022influential citation
• Mechanisms and clinical management of eosinophilic oesophagitis: an overview

  2022cites this paper
• SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS.

  2022cites this paper
• Association between gastroesophageal reflux disease and coronary atherosclerosis

  2022cites this paper
• Drug treatment strategies for eosinophilic esophagitis in adults

  2022cites this paper
• Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline

  2022cites this paper
• Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021

  2022cites this paper
• Multiple Micronutrients, Including Zinc, Selenium and Iron, Are Positively Associated with Anemia in New Zealand Aged Care Residents

  2021influential citation
• Action des inhibiteurs de la pompe à protons sur la sécrétion gastrique acide : mécanismes, effets des traitements au long cours

  2021cites this paper
• Toxicité des inhibiteurs de la pompe à protons

  2021cites this paper
• Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials

  2021cites this paper
• Die konservative Therapie der Refluxkrankheit und ihre Grenzen

  2021cites this paper
• Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol

  2021cites this paper
• Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial

  2021cites this paper
• Adverse Effects of Medications on Micronutrient Status: From Evidence to Guidelines.

  2021cites this paper
• Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population‐Based Cohort Study

  2021cites this paper
• Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study

  2021cites this paper
• Current Status of Chemoprevention in Barrett's Esophagus.

  2021cites this paper
• Postoperative Dysphagia Following Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease

  2020cites this paper
• Cognitive problems of breast cancer survivors on proton pump inhibitors

  2020cites this paper
• Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis

  2020cites this paper
• Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)

  2020cites this paper
• Proton Pump Inhibitors: The Good, Bad, and Ugly.

  2020cites this paper
• Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer

  2020cites this paper
• Proton Pump Inhibitor Long-term Prescription, Is It Safe?

  2020cites this paper
• Recommendations for the diagnosis and practical management of paediatric eosinophilic oesophagitis

  2020cites this paper
• How to advise patients on the risk of chronic proton pump inhibitor therapy.

  2020influential citation
• Latest insights into the hot question of proton pump inhibitor safety - a narrative review.

  2020cites this paper
• Gastric neuroendocrine tumours from long‐term proton pump inhibitor users are indolent tumours with good prognosis

  2020influential citation
• Potential proton pump inhibitor–related adverse effects

  2020cites this paper
• Eosinophilic esophagitis, Barrett's esophagus and esophageal neoplasms in the pediatric patient: a narrative review.

  2020cites this paper
• Side effects of drug treatments for gastro-oesophageal reflux disease: current controversies

  2020cites this paper
• Laryngopharyngeal and Gastroesophageal Reflux: A Comprehensive Guide to Diagnosis, Treatment, and Diet-Based Approaches

  2020cites this paper
• [The dental status of patients with gastroesophageal reflux disease depending on the intake of proton pump inhibitors].

  2020cites this paper
• Who Needs Gastroprotection in 2020?

  2020cites this paper
• Proton Pump Inhibitor Controversies

  2020cites this paper
• Recomendaciones para el diagnóstico y manejo práctico de la esofagitis eosinofílica pediátrica

  2020cites this paper
• Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth.

  2019cites this paper
• Barrett oesophagus

  2019cites this paper
• S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL

  2019cites this paper
• The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract

  2019cites this paper
• Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C

  2019cites this paper
• Properly prescribed, proton pump inhibitors are largely safe, but precautions are needed to prevent potential problems, overuse and misuse

  2019cites this paper
• The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events

  2019cites this paper
• Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem

  2019cites this paper
• Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression.

  2019cites this paper
• Ilaprazole Compared With Rabeprazole in the Treatment of Duodenal Ulcer

  2019cites this paper
• Prevention of overuse: A view on upper gastrointestinal endoscopy

  2019cites this paper
• Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence

  2019cites this paper
• Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility

  2019cites this paper
• Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?

  2019cites this paper
• Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach

  2018cites this paper
• Mistakes in pancreatic cystic neoplasms and how to avoid them

  2018cites this paper
• Long-term Treatment With Proton Pump Inhibitors Is Effective in Children With Eosinophilic Esophagitis

  2018cites this paper
• Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome.

  2018cites this paper
• Reflux Aspiration and Lung Disease

  2018cites this paper
• Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study

  2018cites this paper
• Emerging drugs for eosinophilic esophagitis

  2018cites this paper
• Proton pump inhibitors in the light of clinical studies and safety profile of long term use

  2018cites this paper
• Proton Pump Inhibitors: Are They a Real Threat to the Patient?

  2018cites this paper
• The Role of Proton Pump Inhibitors in the Management of Pediatric Eosinophilic Esophagitis

  2018cites this paper
• Инфекция Helicobacter pylori при длительной терапии кислотозависимых заболеваний ингибиторами протонной помпы(Обзор литературы и резолюция Экспертного совета, 22 марта 2018 г.)

  2018cites this paper
• Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks

  2018cites this paper
• Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

  2018cites this paper
• Use acid-suppressing drugs appropriately with an individualized approach to minimize the risk of infection

  2018cites this paper
• Gastroösophageale Refluxkrankheit – Update 2018

  2018cites this paper
• L’absorption intestinale des vitamines hydrosolubles et liposolubles en pratique clinique

  2018cites this paper
• Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).

  2017cites this paper